68Ga-FAPI PET/CT与18F-FDG PET/CT在评估转移性肛管黑色素瘤伴脑受累治疗反应中的效用比较
本文报道一例59岁转移性黑色素瘤伴脑转移患者,脑放疗后出现神经系统症状。为评估治疗反应及镥-177-FAPI治疗可能性,行18F-FDG PET/CT与68Ga-FAPI-46 PET/CT;18F-FDG PET/CT因治疗后改变无法明确区分肿瘤进展与治疗相关改变,而68Ga-FAPI-46 PET/CT显示多处FAPI摄取增高,提示存活残留病灶,并与MRI所见一致。
要点
- 18F-FDG PET/CT因治疗后改变无法明确区分肿瘤进展与治疗相关改变。
- 68Ga-FAPI-46 PET/CT显示多处FAPI摄取增高,提示存活残留病灶。
- 68Ga-FAPI-46 PET/CT所见与MRI所见一致。
核心结论
- 68Ga-FAPI-46 PET/CT显示多处FAPI摄取增高,提示存活残留病灶,并与MRI所见一致。
研究设计与样本
- 本文为个案报道,患者为59岁转移性黑色素瘤伴脑转移男性,脑放疗后出现神经系统症状。
主要发现
- 18F-FDG PET/CT因治疗后改变无法明确区分肿瘤进展与治疗相关改变。
- 68Ga-FAPI-46 PET/CT显示多处FAPI摄取增高,提示存活残留病灶,并与MRI所见一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 59-year-old man with metastatic melanoma and brain metastases underwent brain radiotherapy. Following treatment, he developed neurological symptoms, prompting further evaluation. To assess the treatment response and possibility of Lutetium-177-FAPI therapy, both 18 F-FDG PET/CT and 68 Ga-FAPI-46 PET/CT scans were performed. The 18 F-FDG PET/CT was inconclusive due to posttreatment changes, making it challenging to distinguish between tumor progression and therapy-related alterations. In contrast, the 68 Ga-FAPI-46 PET/CT revealed multiple areas of increased FAPI uptake, indicative of viable residual lesions and consistent with MRI findings.
引用
- Divband G, Chehrara M, Khodakarim N, et al. Comparative Utility of 68 Ga-FAPI PET/CT and 18 F-FDG PET/CT in Assessing Treatment Response in a Case of Metastatic Anal Melanoma With Brain Involvement. Clin Nucl Med. 2025. PMID: 40795804. doi:10.1097/RLU.0000000000005985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。